2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next year.Take CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA), two biotechs specializing in gene editing. The former's average price target, according to Yahoo! Finance, is $83.60; the latter earns a price target of $50.80 from analysts. That implies an upside of about 66% for CRISPR Therapeutics and 415% for Intellia Therapeutics.These two companies have significantly lagged the market over the past three years. Could they turn around and live up to Wall Street's expectations?Continue reading
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next year.
Take CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA), two biotechs specializing in gene editing. The former's average price target, according to Yahoo! Finance, is $83.60; the latter earns a price target of $50.80 from analysts. That implies an upside of about 66% for CRISPR Therapeutics and 415% for Intellia Therapeutics.
These two companies have significantly lagged the market over the past three years. Could they turn around and live up to Wall Street's expectations?
